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Remacemide hydrochloride is a low-affinity, non-competitive NMDA receptor channel blocker under investigation for the
treatment of epilepsy.
This double-blind, placebo-controlled, multicentre study assessed the safety and efficacy of adjunctive remacemide hy-
drochloride or placebo, in adult patients with refractory epilepsy who were already taking up to three antiepileptic drugs
(including an enzyme-inducer). Patients (n = 262) were randomized to one of three doses of remacemide hydrochloride
(300, 600 or 800 mg/day) or placebo, in a B.I.D. regimen, for up to 14 weeks. Plasma concentrations of carbamazepine (CBZ)
and phenytoin (PHT) were controlled throughout. Patients recorded their seizures on a diary card.
There was an increase in the percentage of responders (defined as a reduction in seizure frequency from baseline ≥50%),
from 15% (9/60) with placebo, to 30% (18/60) in the 800 mg/day group. A pairwise comparison between remacemide hy-
drochloride 800 mg/day and placebo was statistically significant (P = 0.049). Most reported adverse events (mainly CNS and
gastrointestinal) were mild or moderate in severity and dose-dependent.
Adjunctive remacemide hydrochloride treatment was associated with a higher, dose-related responder rate compared with
placebo. The difference reached significance at the highest dose tested (800 mg/day). Remacemide hydrochloride was well
tolerated.
c© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved
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INTRODUCTION
Remacemide hydrochloride is a new antiepilep-
tic drug (AED) with a novel mechanism of ac-
tion. Remacemide and its principal active desg-
lycinyl metabolite, are low affinity, non-competitive
N -methyl-D-aspartic acid (NMDA) receptor channel
blocking agents with additional significant sodium fast
channel blocking activity1. This study was designed
to establish an active dose range for remacemide
hydrochloride in a B.I.D. regimen, as adjunctive
therapy, in refractory patients with epilepsy receiving
hepatic enzyme inducing AEDs. Early studies have
shown that plasma concentrations of remacemide and
its desglycinyl metabolite are reduced in the presence
of hepatic enzyme-inducing drugs such as CBZ and
PHT2, 3. In turn, interaction studies have shown that
remacemide increases plasma concentrations of CBZ3
and PHT4 by inhibiting their metabolism. Plasma con-
centrations of CBZ and PHT were maintained within
pre-determined limits by adjusting the dose of these
drugs, as necessary, on an individual patient basis.
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Fig. 1: Study design.
MATERIALS AND METHODS
The study was approved by the appropriate ethics
committee at each centre. All patients gave informed
consent before study entry and the study was
conducted in accordance with the Declaration of
Helsinki. Patients were recruited at 26 centres in
Canada, Australia and Germany. The first patient
entered the study in November 1993 and the last
patient completed in November 1995.
Study population
Male and female patients aged between 18 and 70
years, who had been diagnosed with epilepsy for at
least one year and who were refractory to conventional
therapies, were enrolled. Each patient was taking
up to three AEDs, including at least one hepatic
enzyme inducing drug (CBZ, PHT, phenobarbital or
primidone). To enter the double-blind phase, patients
had to have an average seizure frequency of at least
four seizures per month during baseline. Patients were
excluded if they had other significant medical history
or a history of pseudoseizures. Women of child-
bearing potential were excluded unless, in the opinion
of the investigator, they were reliable users of an
effective contraceptive method.
A total of 240 patients were planned to complete the
study (60 in each of four treatment groups). Assuming
that 10% of patients in the placebo group would
respond to treatment (response to treatment defined as
a 50% or greater reduction in seizure frequency when
compared with baseline), this sample size allowed
the detection of a true difference of 23% or greater
between the active treatment groups and placebo,
based on two-tailed statistical tests with a 5% level of
significance and 80% power.
Study design
The study design is shown in Fig. 1. Patients who
were taking CBZ or PHT had a 2- to 6-week run-in
period, during which the investigator established each
patient on an optimum regimen of CBZ or PHT. At the
end of the run-in period, patients entered an 8-week
baseline period during which their optimal dose was
maintained and they were assessed every 2 weeks and
provided blood samples for measurement of CBZ or
PHT. These results were used in conjunction with a
Shewhart control chart5 to define a ‘target range’ for
CBZ or PHT concentration for each patient. During
the baseline period, patients continued to take the dose
of CBZ or PHT on which they were stabilized.
After baseline, patients entered the double-blind
period and were randomized to receive either placebo
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or one of three doses of remacemide hydrochloride
(300, 600 or 800 mg/day) in a twice-daily regimen for
14 weeks. All patients randomized to active treatment
received 300 mg/day during the first week. During
the second week, patients randomized to the 600 and
800 mg/day groups received 600 mg/day. At the
end of the second week, patients randomized to the
800 mg/day group were titrated up to 800 mg/day.
By the end of the third week, all patients had reached
their allocated dose. During the next 3 weeks, the
investigator adjusted each patient’s dose of CBZ
or PHT, if necessary, until plasma concentrations
were stable and within the target range. At the
end of the dose titration phase (6 weeks in total),
patients continued to receive study treatment for the
remaining eight weeks of the double-blind period (the
continuation phase). Patients who could not tolerate
their allocated dose received a dose reduction and
continued in the study.
At the end of the double-blind period, patients
chose either to discontinue treatment or to enter an
open-label extension study. For patients who chose to
withdraw, study treatment was withdrawn gradually
over 12 days to reduce the theoretical risk of rebound
seizure activity. Patients who chose to continue treat-
ment entered a 4-week double-blind transition period,
during which the dose of remacemide was adjusted
gradually so that all patients entered an open long-term
extension study on a dose of 800 mg/day (patients
who could not tolerate the 800 mg/day dose could
enter the extension study on a dose of 600 mg/day).
Each day throughout the study, patients recorded
adverse events, seizure type and frequency on a diary
card. At each clinic visit, safety was assessed by clini-
cal examination, electrocardiogram (ECG) and routine
laboratory tests. Blood samples were taken at the end
of the baseline period and throughout the double-blind
period for measurements of plasma concentrations
of remacemide and its desglycinyl metabolite. Blood
samples were taken for measurement of other AEDs,
as appropriate.
Outcome measures
The primary outcome measure was the percentage
of patients who responded to treatment, i.e. who
had a 50% or greater reduction in seizure frequency
compared with baseline. An additional efficacy mea-
sure was the median percentage reduction in monthly
seizure frequency.
The safety variables were adverse events, haema-
tology and biochemistry, urinalysis, ECGs and vital
signs.
Statistical analysis
The null hypothesis was that placebo and remacemide
were equivalent. The analysis plan specified that the
efficacy analyses would be based on all patients who
completed at least 14 days of study treatment follow-
ing the titration period. The number of responders (i.e.
≥50% reduction in seizure frequency) was compared
using a chi-square test. Pairwise comparisons between
groups were also carried out, again using a chi-
square test. The Kruskal–Wallis test6 was used to
compare each of the other efficacy variables between
treatments. All randomized patients were included in
the safety analyses. Analysis of variance was used
to compare treatment groups for laboratory variables,
ECG parameters and vital signs.
An adjustment was made for centre in most
analyses. Data from each time point was analysed
separately using analysis of variance with treatment,
centre and treatment-by-centre interactions as factors.
No adjustment was made for multiple testing.
RESULTS
Patient characteristics
The four treatment groups were similar with respect to
age, height and weight but there was a difference in the
male:female ratio in the placebo and 300 mg groups.
The majority of patients were white (95%). The other
races were evenly distributed among the treatment
groups. Patient demographics are summarized in
Table 1.
Table 1: Patient characteristics (mean ± SD).
Placebo 300 mg 600 mg 800 mg
n = 64 n = 66 n = 64 n = 68
Age (years) 37.8± 11.0 37.6± 9.6 36.7± 9.6 34.4± 11.5
Height (cm) 172.5± 9.7 167.7± 9.6 168.0± 11.0 168.6± 11.0
Weight (kg) 80.5± 17.8 74.4± 18.8 72.6± 15.3 76.8± 17.2
Sex (M :F) 45 : 19 26 : 40 31 : 33 35 : 33
Table 2 shows the number of AEDs taken by each
patient at entry; the majority (61%) were taking two
AEDs. Overall, the most frequently taken AEDs were;
CBZ, PHT, sodium valproate and clobazam.
Table 2: Number of antiepileptic drugs taken by each patient
at entry to the study.
Number of Placebo 300 mg 600 mg 800 mg
AEDs n = 64 n = 66 n = 64 n = 68
1 16 14 17 12
2 38 39 36 46
3 10 13 11 9
4 0 0 0 1
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The mean duration of epilepsy was similar in
each treatment group (between 24 and 28 years) and
aetiology was most frequently recorded as idiopathic.
These details are shown in Table 3.
Table 3: Duration (mean ± SD) and aetiology of epilepsy.
Placebo 300 mg 600 mg 800 mg
n = 64 n = 66 n = 64 n = 68
Duration (years) 27± 13 28± 10 24± 11 24± 12
Aetiology
Idiopathic/cryptogenic 30 38 36 36
Birth trauma 9 9 6 7
Head injury 7 5 8 9
Cerebral infection 9 5 5 4
Other 9 9 9 12
In all four treatment groups, complex partial
seizures were the most common seizure. Only two
patients had seizures which were unclassified. Table 4
summarizes patients’ seizure classification; many
patients recorded more than one type of seizure.
Table 4: Seizure classification.
Placebo 300 mg 600 mg 800 mg
Type of Seizurea n = 64 n = 66 n = 64 n = 68
Simple partial 33 28 23 38
Complex partial 47 51 56 56
Secondary generalized 31 32 33 40
Primary generalized 7 13 12 5
Unclassified 0 0 1 1
a Some patients had more than one type of seizure.
Disposition of patients
A total of 262 patients were randomized and received
study treatment, with 232 completing the double-blind
period. The numbers of patients at each stage of the
study are shown in Fig. 2. Patient withdrawals during
the double-blind treatment period are summarized
in Table 5. There were more withdrawals due to
adverse events in the 600 and 800 mg/day groups
than in the 300 mg/day and placebo groups during
the double-blind period. All 262 patients who received
treatment were included in the safety analyses. A total
of 237 patients completed at least 14 days’ treatment
following the titration phase and were included in
the efficacy analysis; five of these patients withdrew
before completing the double-blind period.
Table 5: Number of patients withdrawn during the
double-blind treatment period.
Placebo 300 mg 600 mg 800 mg
Reasona n = 64 n = 66 n = 64 n = 68
Worsening epilepsy 0 0 2 (3%) 1 (1%)
Other adverse event 4 (6%) 2 (3%) 7 (11%) 8 (12%)
No improvement in symptoms 0 0 0 1 (1%)
Withdrew consent 0 3 (5%) 1 (2%) 0
Other 0 1 (2%) 1 (2%) 2 (3%)
Total 4 (6%) 5 (8%) 10 (16%) 11 (16%)
a Patients may have more than one reason for withdrawal.
Efficacy results
Responder rate
Figure 3 shows the dose-related increase in the
percentage of patients with a reduction of at least
50% in seizure frequency between baseline and
continuation phase. Responder rates are also shown
in Table 6. The responder rate was 15% (9/60) of
patients in the placebo group and 30% (18/60) of
patients in the remacemide hydrochloride 800 mg/day
group. Although there was no statistically significant
difference among treatments overall (P = 0.208),
a pairwise comparison between 800 mg/day and
placebo was statistically significant in favour of
remacemide hydrochloride (P = 0.049).
Table 6: Percentage of patients with a reduction from
baseline in monthly seizure frequency of at least 50%.
Placebo 300 mg 600 mg 800 mg
Treatment group n = 60 n = 61 n = 56 n = 60
% patients 15 18 21 30
(95% CI) (6 to 24) (8 to 28) (11 to 32) (18 to 42)
P = 0.208 (overall difference among treatments).
Four patients became seizure-free during the study,
two in the placebo group, one in the 600 mg/day group
and one in the 800 mg/day group.
In a subsequent analysis, the proportion of patients
whose seizure frequencies increased by at least 100%
was found to be 3% in the placebo group, 2% in the
300 mg/day group, 4% in the 600 mg/day group and
0% in the 800 mg/day group.
Seizure frequency
Figure 4 shows that the median monthly seizure
frequency decreased in all four groups over the course
of the study. The largest median percentage change
from baseline was in the remacemide hydrochloride
800 mg/day group (decrease of 31.4%), with
the smallest median change in the placebo group
(decrease of 10.1%). However, due to large variability,
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Fig. 2: Number of patients at each stage of the study.
Fig. 3: Differences in responder rates between remacemide and placebo with 95% confidence intervals.
this trend did not reach statistical significance (P =
0.110).
Safety results
Adverse events
There was a dose-dependent increase in the percentage
of patients reporting adverse events during the contin-
uation phase: from 59% (36 patients) in the placebo
group, to 78% (47 patients) in the 800 mg/day group.
Most events were mild to moderate in severity and
resolved without further treatment or discontinuation
of study drug. The most frequently occurring adverse
event during study treatment was headache, but this
occurred to a similar extent in all the treatment
groups. Table 7 summarizes the adverse events that
were reported by five or more patients in any
treatment group.
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Table 7: Numbers of patients with most frequently occurring adverse events by randomized treatment group.
Placebo 300 mg 600 mg 800 mg
Adverse event n = 64 n = 66 n = 64 n = 68
Body as a whole:
Drug level increased 2 5 9 2
Fatigue 7 13 12 153
Fever 3 5 3 2
Influenza-like symptoms 5 4 3 5
Physical injury 9 11 8 3
Central and peripheral nervous system:
Convulsions 1 5 3 2
Convulsions aggravated 6 2 3 5
Dizziness 8 18 22 30
Gait abnormal 1 1 8 4
Headache 11 11 15 14
Nystagmus 6 4 5 5
Tremor 2 3 4 6
Gastrointestinal disorders:
Abdominal pain 3 12 9 14
Diarrhoea 4 5 4 5
Dyspepsia 4 2 5 9
Nausea 8 6 10 16
Vomiting 0 3 9 10
Psychiatric disorders:
Confusion 1 1 7 0
Somnolence 6 8 6 14
Respiratory system:
Coughing 2 5 1 0
Pharyngitis 4 7 2 3
Upper respiratory tract infection 9 11 8 10
Vision disorders:
Diplopia 3 4 4 11
Vision abnormal 2 6 8 1
– 50
– 40
– 30
– 20
– 10
0
10
Placebo 300 mg 600mg 800mg
Fig. 4: Percentage change in median monthly seizure
frequency from baseline, with 95% confidence intervals.
Table 8: Patients with biochemistry values >100% above the
normal range during treatment.
Placebo 300 mg 600 mg 800 mg
Gamma GT 17 17 11 17
SGOT 2 3 1 0
SGPT 3 1 5 3
Triglycerides 4 4 4 5
Total cholesterol: HDL cholesterol 3 4 5 1
During the double-blind period, three patients
in the placebo group reported five serious events
and 18 patients in the three remacemide treatment
groups reported 18 serious events. Ten events (all
in the remacemide groups) were considered by the
investigator to be possibly related to treatment;
five of these were hospitalizations for aggravated
seizures. Two patients had a range of central nervous
system (CNS), and visual disorder symptoms and one
patient had a range of psychiatric symptoms. The other
events were gastritis (one patient) and raised liver
enzymes (one patient).
A total of 21 patients were withdrawn from double-
blind treatment due to adverse events. Table 5 sum-
marises patient withdrawals. Adverse events leading
to withdrawal were mainly CNS or gastrointestinal-
related.
Other safety assessments
Details of the few patients who developed laboratory
abnormalities during the study are summarized in
Table 8. There were no clinically significant trends
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Fig. 5: Mean % change in carbamazepine plasma concentration from baseline during the double-blind continuation phase.
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Fig. 6: Mean % change in phenytoin plasma concentration from baseline during the double-blind continuation phase.
to suggest that any biochemical abnormalities were
related to treatment with remacemide hydrochloride.
Similarly, there were no clinically significant dif-
ferences between the groups for changes in ECG
parameters or vital signs.
Carbamazepine and phenytoin control
Plasma levels of CBZ and PHT were well controlled
during the study. Mean levels of both drugs increased
slightly following administration of remacemide hy-
drochloride. These changes are illustrated in Figs 5
and 6. In the case of CBZ, increases in plasma concen-
tration were independent of the dose of remacemide
hydrochloride, and the mean CBZ change was similar
in responders and non-responders. For PHT there
was wide variation in plasma concentrations in all
treatment groups. There was no correlation between
the percentage reduction in seizure frequency and
plasma concentration of either CBZ or PHT.
Pharmacokinetics of remacemide and its
desglycinyl metabolite
Despite considerable variability across treatment
groups, plasma concentrations of remacemide and
its desglycinyl metabolite were approximately pro-
portional to dose. Steady-state plasma concentrations
for each one hour period over the dosing interval,
for the parent drug and metabolite, are illustrated in
Figs 7 and 8 respectively. No discernible threshold
plasma concentration was identified for efficacy or
adverse events and there was no apparent difference
between responders and non-responders in plasma
concentrations.
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DISCUSSION
Assessment based on the key efficacy variable, re-
sponder rate, showed that remacemide hydrochloride
800 mg/day in a twice-daily regimen was significantly
better than placebo at halving the number of seizures.
The responder rate of 30% in the remacemide
800 mg/day group was similar to results for other
AEDs7, but the responder rate in the placebo group
(15%) was higher than expected. Few patients became
seizure free but this was not unexpected in such a
highly refractory population.
Although the median percentage change in seizure
frequency was not statistically significantly different
among the treatment groups, the reduction in the
800 mg/day group (26%) was over three times greater
than that in the placebo group (8%). Subsequent
analysis has shown that the large variation in seizure
frequency was not due to worsening of seizures in a
proportion of patients.
Optimized plasma concentrations of CBZ and PHT
were maintained successfully by regular monitoring
and dose adjustments. There was no correlation
between the concentration of either drug and the re-
ductions in seizures, indicating that the improvements
seen were not due to increases in CBZ or PHT levels.
The incidence of adverse events in this study was
reflective of the population. Almost half of the patients
(46%) reported adverse events during baseline, before
taking study medication. The adverse event profile
of remacemide was consistent with that from other
studies in a similar patient population. CNS-related
adverse events, such as those seen with remacemide
hydrochloride in this study, are common to the
majority of AEDs8.
The incidence of serious adverse events was no
greater in the active treatment groups than in the
placebo group and was no greater during double-blind
treatment than during baseline.
The laboratory, ECG and vital sign measurements
showed no significant changes with remacemide
hydrochloride treatment.
In conclusion, there was a dose-dependent increase
in the number of patients who had a ≥50% reduc-
tion in seizure frequency following treatment with
remacemide hydrochloride compared with placebo;
this reached statistical significance at the highest
dose tested (800 mg/day). Remacemide hydrochloride
doses of 300 and 600 mg/day appeared to be
sub-optimal for hepatic enzyme-induced patients in
this study.
Remacemide hydrochloride appeared to be
generally well tolerated, with few serious adverse
events and few withdrawals due to adverse events.
Adverse events which appeared to distinguish
remacemide hydrochloride from placebo were CNS
and gastrointestinal-related.
Plasma concentrations of remacemide and the desg-
lycinyl metabolite were variable following a particular
dose but were broadly proportional to dose. Plasma
concentrations of carbamazepine and phenytoin were
successfully maintained within ‘target’ ranges for each
individual.
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